Accelerator™ Drug Development
360° CDMO and CRO solutions
Supporting your aspiration to get treatments to patients faster.
Developing new therapies is inherently complex. Scientific uncertainty, operational fragmentation, and handoffs across multiple vendors can introduce delays, miscommunication, and avoidable risk—jeopardizing the success of your program.
Thermo Fisher Scientific addresses these challenges head-on with Accelerator™ Drug Development, a coordinated suite of solutions that integrates CDMO and CRO capabilities across clinical research, manufacturing, and clinical supply.
Designed to support programs across therapeutic areas and drug modalities, these connected capabilities reduce inefficiencies, strengthen continuity, and help ensure predictable progress from preclinical development through commercialization.
Discover what makes Accelerator™ Drug Development unique,
directly from our team.
Working with a single, integrated partner simplifies your experience, eliminates timeline gaps, and proactively mitigates risk.
Innovative solutions across drug modalities and therapeutic areas meet your unique requirements throughout the development journey.
A collaborative team with holistic oversight and integrated expertise across all phases of development, fully invested in your success.
Featured resources
Value reimagined: Unlocking ROI in drug development
Research from the Tufts Center for the Study of Drug Development quantifies the positive impact of aligning CDMO, CRO, and clinical supply services under one partner.
See the real-world impact of Accelerator™ Drug Development
We’ve supported hundreds of biotech and biopharma sponsors of all sizes in mitigating risk and driving efficiency through our integrated approach.
Transforming the pharmaceutical value chain
Learn more about how our flexible model can streamline innovation and adapt to your ever-evolving needs.
Featured solutions
Path to IND for biologics
Our industry-leading Path to IND novel process development platform is designed to supercharge your biologics program timeline—taking you from DNA to final drug product, packed and labeled to begin Phase I clinical trials in tandem with IND/IMPD submission. All without compromising quality. In fact, our quality is better than ever—our new cell line delivers antibody titers of up to 8 g/L.*
Key benefits:
- Speed to market: Going from DNA to IND submission and Phase I clinical trials in as few as 9 months* gives you a competitive advantage, getting treatments to patients faster.
- Advanced technology: Path to IND leverages AI/ML, transposase, and afucosylated technology, as well as high-throughput capital equipment to tailor-make your biologic.
- Expertise and support: Access our global network of state-of-the-art facilities and leading experts in the laboratory, regulatory, and quality assurance fields.
*Terms and conditions: Titer levels provided are estimates based on third-party results and may vary depending on molecule type or other factors. The timeline from DNA to drug product and the start of clinical trials for all Path to IND for biologics options may vary depending on molecule type or other factors and are estimates to be finalized once third-party cell line development dates are available and confirmed. The 9-month timeline involves additional risk.
Drug Development Digital Solutions
Thermo Fisher Scientific's Drug Development Digital Solutions help tackle the significant challenges facing today’s sponsors with innovative, AI-enabled technology. Our purpose-built capabilities speed up and optimize every phase of clinical development.
Our integrated digital ecosystem sets new standards in drug development, enabling biotech and biopharmaceutical companies to conduct faster, higher-quality trials with greater confidence. Benefits include:
- Faster study startups
- Smarter site selection
- Cleaner data management
- Increased transparency
- Streamlined regulatory compliance
Accelerator™ Drug Development, 360° CDMO and CRO solutions
Contract development and manufacturing organization (CDMO) services
Flexible and scalable CDMO services and solutions for small molecules, large molecules, and advanced therapies.
- Discovery and preclinical development
- Formulation development
- Analytical testing
- Clinical trial services
- Clinical and commercial manufacturing
- Packaging, labeling, and distribution
- Regulatory support
Contract research organization (CRO) services
Full-service Phase I-IV solutions and customized strategies designed to help you deliver life-changing therapies with speed and efficiency.
- Early phase through post-approval clinical research
- Deep and cross-therapeutic expertise
- Phase I-IV clinical trial management
- Regulatory affairs strategy
- PPD Laboratory Services (GMP, central lab, bioanalytical, vaccine sciences)
- Patient-first solutions
- Digital and AI solutions
- Global clinical site selection and management
- Clinical supplies and logistics
- HEOR and market access
- Real-world evidence/real-world data
Clinical supply services
End-to-end clinical trial supply services for research studies of every size and scope.
- Clinical packaging
- Clinical labeling
- Clinical logistics and distribution
- Strategic comparator sourcing
- Cold chain logistics and management
- Enhanced demand planning
- Clinical ancillary supplies
Frequently asked questions (FAQs)
A contract development and manufacturing organization (CDMO) is a company that provides outsourced drug development and manufacturing services to biotechnology and pharmaceutical companies. The wide range of CDMO offerings may include formulation, clinical and commercial manufacturing, regulatory support, product packaging, supply chain management, quality assurance, and technology transfer solutions. A clinical research organization (CRO) supports biotechnology and pharmaceutical companies by managing and conducting various aspects of clinical research, such as clinical trial design, site selection, patient recruitment, clinical monitoring, data management, medical writing, and project management.
A CRDMO, or contract research, development, and manufacturing organization, is a type of outsourcing partner that combines the services traditionally offered by clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs). CRDMOs provide a comprehensive, end-to-end solution for drug development, encompassing initial research, clinical trials, development, manufacturing, and supply chain management.
By working with a CRDMO, drug developers can reduce handoffs and inefficiencies to more confidently navigate the complex process of bringing new therapies to market—both locally and around the globe. Specific benefits include cross-team coordination, accelerated time-to-market, improved quality, consistency, and reliability, greater control over projects, and enhanced regulatory compliance.
CRDMOs offer enhanced drug development by integrating clinical research, manufacturing, and supply functions into a single-vendor framework. This cohesive model addresses inefficiencies, miscommunication, and delays inherent in traditional fragmented outsourcing, where separate vendors handle different stages. By streamlining services, CRDMOs reduce coordination gaps, data silos, and fragmented processes, leading to faster decision-making, improved data flow, and better alignment across critical functions. This integration is particularly beneficial in high-stakes therapeutic areas such as oncology, neurology, and rare diseases, where agility and precision are crucial to delivering innovative treatments to patients.
Related resources